Pramlintide

This page contains recent news articles, when available, and an overview of Pramlintide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Amylin Pharmaceuticals to Webcast First Quarter Results  -  ‎Apr 9, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release)

Amylin Pharmaceuticals Provides Shareholders with Update Regarding ...  -  ‎Apr 2, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release)

Amylin gears for 3-way proxy fight as Carl Icahn names five ...  -  ‎Apr 8, 2009‎
The company also manufactures other diabetes drugs, like Symlin, or pramlintide acetate, injection, as well as obesity-treatment drugs. RTT News

PennyPerformers.com: "Penny Stocks that Perform" picks are: AMLN ...  -  ‎Mar 30, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) Trading Markets (press release)

Creeping Waistline Speeds Path to Grave, Study Says  -  18 Mar 2009
Amylin is working on a drug that combines pramlintide, the active ingredient in its diabetes drug Symlin, with leptin, a hormone tied to hunger. Bloomberg

마법 같�?� 차세대 비만치료제를 찾아서!  -  18 Mar 2009
...여기서는 �?�미 합성 렙틴�?� 메트�?렙틴(metreleptin)과 합성 아밀린�?� 프람린타�?�드(pramlintide)�?� 제조�? 성공, �?�들�?� 결합한 차세대 비만치료제 개발�? 뛰어들었다 서울경제

Amylin Pharmaceuticals to Present at Cowen and Company Annual ...  -  ‎Mar 10, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release)

Insulin and Weight Gain  -  ‎Mar 1, 2009‎
13-16 Combining insulin therapies with agents that have positive or neutral weight effects, such as metformin and pramlintide, also can minimize ADVANCE for Physician Assistants

Prandial Not Superior to Basal Strategies in Diabetic Survivors of ...  -  ‎Mar 4, 2009‎
...acarbose or pramlintide, which are approved with insulin) and whether the study will be repeated with newer drugs that more effectively lower Medscape

�?有糖尿病之急性心肌梗塞存活者而言膳食控制並未優於一些基本策略  -  ‎Mar 7, 2009‎
Ceriello醫師寫�?�，肯定的是，如果使用其他�?後藥物加上胰島素來�?�到目標，是�?�會�?�得�?一樣的�?果(例如acarbose或者pramlintide這些核准併用胰島素的藥物)，使用�?低臺灣新浪網

�?肥�?�开�?�在�?��?�中行进  -  ‎Feb 24, 2009‎
Amylin公�?�的普兰林肽(Pramlintide)是天然存在的胰激素Amylin的类似物，已获准用于糖尿病治疗。现�?�现该化�?�物对肥胖有效。在一项为期52周的Ⅱ期临床试验中，�?�独用中国医药报

Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice ...  -  Jan 26, 2009
Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release),

A taste of dysglycemia  -  Jan 9, 2009
The patient is at risk for hyperglycemia: have her take pramlintide with every glass of wine. The patient will not be affected because she will spit out the Endocrine Today,

Amylin Pharmaceuticals, Inc Q4 2008 Earnings Call Transcript  -  Jan 27, 2009
We previously announced our commitment to pursue a medicine for obesity that is a combination of analogs of human hormones amylin and leptin: Pramlintide, Seeking Alpha,

Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices  -  Jan 30, 2009
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release),

Amylin Pharmaceuticals to Webcast Year-End Results  -  Jan 21, 2009
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release),

Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities  -  Jan 12, 2009
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release),

Amylin Pharmaceuticals to Webcast Year-End Results  -  Jan 22, 2009
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PharmaLive.com (press release),

Obesity: Reviving the promise of leptin  -  Jan 17, 2009
Amylin is testing leptin in combination with its diabetes drug, pramlintide. The current study was supported by the Timothy Murphy Fund, Junior Faculty The Virtual Medical Centre,

Lilly Drug Facing FDA Delay  -  Dec 8, 2008
Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) Inside INdiana Business (press release),

Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide ...  -  Dec 9, 2008
Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PipelineReview.com (press release),

Amylin Pharmaceuticals Announces Strategic Restructuring and ...  -  Nov 10, 2008
The Company remains fully staffed to grow product revenue from BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection and bring MarketWatch

Amylin Pharmaceuticals to Present at Lazard Capital Markets ...  -  Nov 13, 2008
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) MarketWatch

Solvay Ends Research on Experimental Obesity Drug  -  Nov 18, 2008
Lorcaserin, pramlintide/leptin and other emerging novel therapies will capture 80 percent of the total obesity market in 2016 as doctors’ switch from the Network Médica,

New consensus statement on the medical management of type 2 diabetes  -  Nov 18, 2008
Other agents, including alpha-glucosidase inhibitors, glinides, pramlintide (Symlin, Amylin) and DDP-IV inhibitors, were not included in the algorithm Endocrine Today,

Company and People Notes: Amylin, AP Pharma, Avigen, and ...  -  Nov 13, 2008
The company remains fully staffed to grow product revenue from “Byetta�? (exenatide) injection and “Symlin�? (pramlintide acetate) injection and bring a Pharmaceutical Technology Magazine,

Endocrinology & Metabolism News  -  Nov 5, 2008
...(Diabetes Care [September 2008] 31 (9):1777) Pramlintide treatment, when used over 12 months as an adjunct to lifestyle intervention and at either a Journal of Clinical Endocrinology and Metabolism,

Noteworthy Developments in Biotech  -  Nov 2, 2008
...short of some of the other candidates currently in late-stage trials (~20 to 25 lbs after 24 weeks for Qnexa, Contrave, and pramlintide/metreleptin). Zacks.com,

Arena: No Near-Term Relief  -  Oct 31, 2008
...short of some of the other candidates currently in late-stage trials (~20 to 25 lbs after 24 weeks for Qnexa, Contrave, and pramlintide/metreleptin). Zacks.com,

GAZETA: Pesquisa sobre obesidade pode estar em risco  -  Oct 27, 2008
Nos EUA, a Amylin Pharmaceuticals está testando sua terapia combinada pramlintide para obesidade. A Arena Pharmaceuticals, com sede em San Diego, Gazeta Mercantil,

Amylin Pharmaceuticals to Webcast Third Quarter Results  -  Oct 16, 2008
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PharmaLive.com (press release),

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity ...  -  Oct 2, 2008
In addition to Amylin's lead clinical-stage programs in obesity, pramlintide/metreleptin and AC2307, new findings will also be presented on various PharmaLive.com (press release),

Amylin Resurrects Obesity Drug, in New Combination with Diabetes ...  -  Oct 4, 2008
The Amylin approach is to use pramlintide, a genetically modified version of a hormone that’s secreted from the pancreas to slow down stomach emptying. Xconomy,

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity ...  -  Oct 1, 2008
In addition to Amylin's lead clinical-stage programs in obesity, pramlintide/metreleptin and AC2307, new findings will also be presented on various istockAnalyst.com (press release),

[비만치료제]세계 비만치료제 시장 전�?  -  Oct 7, 2008
...�? �?��?�계열로 아밀린(Amylin)�?� ‘프람린티드/렙틴’(pramlintide/leptin) 복합제�?� 주목�?�다. 프람린티드는 췌장분비 신경호르몬�?� 아밀린�?� 합성 유사체로 �?욕·�?��? 디지틀보사,

Adding Sibutramine or Phentermine to Pramlintide Increases Weight ...  -  Sep 10, 2008
By Jill Stein ROME -- September 9, 2008 -- Using sibutramine or phentermine in tandem with pramlintide can enhance weight loss in overweight or obese DG News

Diabetes drug may help treat obesity  -  Sep 10, 2008
Pramlintide, currently approved by the FDA for diabetes to take in combination with insulin to control their blood sugar levels. Reuters

BIOTECH: Master switch for hunger, reproduction, identified  -  Aug 31, 2008
Amylin licensed the rights to the leptin drug from Amgen, and is now testing it in human clinical trials in combination with pramlintide, North County Times,

Multihormonal Treatment Approaches and the Diabetes-Obesity Continuum  -  Aug 26, 2008
Dr. Wysham will discuss an off-label or investigational use regarding pramlintide during her presentation. Disclosure: Dr. Aronoff: Grants/Research Support: Medscape (subscription)

Triple Top Breakouts Featuring Market Mover Amylin Pharmaceuticals ...  -  Aug 19, 2008
It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with type II diabetes… TransWorldNews (press release),

Amylin and Lilly Set Date and Time for Conference Call  -  Aug 25, 2008
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) HotStocked,

Patients Taking BYETTA Also Reduced Food Intake  -  Sep 9, 2008
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PipelineReview.com (press release),

Market Report -- Short Stories (AMLN)  -  Aug 25, 2008
They believe that Amylin's investigational obesity combination therapy (pramlintide/leptin) will increase in visibility in 2009 as Phase IIb results are MSN Money

[�?�학] 당뇨병 약으로 체중 줄�?�다(?)  -  Sep 11, 2008
2형당뇨병 치료제�?� 프람린티드(pramlintide)가 당뇨병 환�?가 아닌 사람들�?� 체중�?� 줄�?�는 �?� �?�움�?� �?�다는 연구결과가 나왔다. �?� 약�?� �?산-�?매하는 애밀린 제약 매�?�경제,

당뇨병 치료약, 비만 치료제로 효과 충분  -  Sep 11, 2008
...당뇨병 치료약제 프람린타�?�드(pramlintide)�?� 체중 �?소효과를 확�?�해 주는 연구결과가 9월호 Diabetes Care지�? 실렸다. 프람린타�?�드는 미국내 �?품명 ‘시 메디게�?�트뉴스,

Amylin Pharmaceuticals to Webcast Second Quarter Results  -  Jul 15, 2008
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) Earthtimes (press release),

Amylin Pharmaceuticals Reports Second Quarter Financial Results  -  Jul 21, 2008
Initiated a Phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human Earthtimes (press release),

Drug Makers Seek Antiobesity Blockbuster  -  Jul 28, 2008
Another drug, Amylin Pharmaceuticals Inc.'s combination of pramlintide, also for diabetes, and metreleptin, an analogue of a hormone, reduced body weight on Wall Street Journal

Amylin Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript  -  Jul 21, 2008
We previously announced our commitment to pursue a medicine for obesity that is a combination of pramlintide, an analog of human amylin and metreleptin, Seeking Alpha,

Prevention, Management and Treatment Strategies for the Treatment ...  -  Jul 21, 2008
Pharmacological alternatives are thoroughly explored with individual chapters on sibutramine and orlistat (both FDA approved) and pramlintide (currently Informa Healthcare,

Regaining lost weight? Blame evolution  -  Jul 15, 2008
Amylin Pharmaceuticals continues to research that possibility and is in Phase 2 trials of a combination of leptin and pramlintide, a diabetes drug. Arizona Daily Star,

BUYINS.NET: (AMLN) SqueezeTrigger Price is $31.367. There is ...  -  Aug 7, 2008
The Company has two approved products, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, Trading Markets (press release),

Amylin Pharmaceuticals to Present Promising Data From Diabetes and ...  -  02 Jun 2008
Oral Late Breaker: "Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment in Patients with Type 2 Diabetes" will be presented by Matthew Riddle, Earthtimes (press release),

Weight-loss-maintenance drugs tested  -  May 30, 2008
In 2005, Amylin produced a drug, pramlintide, that helps lower blood sugar in diabetics who have uncontrolled blood sugar despite therapy with other drugs. Los Angeles Times,

Obesity market set for huge growth  -  Jun 1, 2008
Market growth will be fueled by a number of therapies, the report said, including from Arena Pharmaceuticals' lorcaserin and Amylin's pramlintide/leptin Medical Marketing and Media,

Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical ...  -  May 5, 2008
About Pramlintide and Metreleptin Pramlintide is a synthetic analog of amylin, a neurohormone secreted by the pancreas that is known to play a role in the PR Newswire (press release),

Amylin Pharma Commences Phase 2B Dose-Ranging Study Of Pramlintide ...  -  May 5, 2008
The company said that the Phase 2B study would include a broad range of overweight and obese subjects and would compare various pramlintide/metreleptin RTT News,

Amylin Pharmaceuticals to Present at FBR Capital Markets Investor ...  -  May 22, 2008
Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release),

Amylin Starts Phase IIb Obesity Trial  -  May 6, 2008
Amylin Pharmaceuticals has initiated a Phase IIb clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone RedOrbit,

Amylin Pharmaceuticals, Inc. at Bank of America Securities Health ...  -  May 27, 2008
Last week, we announced initiation of Phase 2B Dose-Ranging Clinical Study with a combination of pramlintide, an analog of human amylin, and metreleptin, Insurance News Net (press release),

Examine The Fastest Growing Biotechnology Companies: Growth ...  -  May 12, 2008
LAR program 173 Obesity product development program 173 Pramlintide 173 Pramlintide and Leptin 174 Pramlintide PYY 3-36 174 Chapter 8 Trimeris, Earthtimes (press release),

Q1 2008 Amylin Pharmaceuticals, Inc. Earnings Conference Call - Final  -  May 5, 2008
In November of 2007, we announced our commitment to pursue a medicine for obesity that is a combination of pramlintide, an analogue of human amylin, Insurance News Net (press release),

Anhydroglucitol Marker Gives Doctors Better Look at Postprandial ...  -  May 22, 2008
...pramlintide, sitagliptin, and biphasic insulin, specifically looking at how Hb A1C and anhydroglucitol responded to glucose after consumption of a meal. DG News

Research and Markets: New Report Examines the Interplay Between ...  -  May 29, 2008
Amylin/Lilly) - Exenatide LAR (Lilly/Amylin/Alkermes) - Symlin (pramlintide; Amylin) - Pramlintide + Recombinant Leptin (r-metHuLeptin) (Amylin/Amgen) PR-Inside.com (Pressemitteilung),

Market Report -- In Play (AMLN)  -  May 5, 2008
Amylin Pharmaceuticals initiates phase 2B dose-ranging clinical study of pramlintide/metreleptin combination treatment in obesity The co announces the MSN Money

Osiris Announces First Quarter 2008 Financial Results Conference ...  -  May 6, 2008
Inc. (NASDAQ: AMLN) recently announced the initiation of a Phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of Financial News USA (press release),

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.